PIK3R2 (Phosphoinositide-3-Kinase Regulatory Subunit 2) encodes the p85β protein, a critical regulatory subunit of class I phosphoinositide 3-kinase (PI3K). This gene plays a fundamental role in cellular signaling pathways that control cell survival, growth, metabolism, and migration. In the central nervous system, PIK3R2-mediated PI3K/Akt signaling is essential for neuronal development, synaptic plasticity, and protection against neurodegenerative processes[1].
The PI3K/Akt pathway is one of the most important cell survival pathways in neurons. Activation of this cascade protects against apoptosis, regulates protein synthesis through mTORC1, controls glucose metabolism, and modulates synaptic function. Dysregulation of PI3K/Akt signaling has been strongly implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders[2].
The human PIK3R2 gene is located on chromosome 19q13.2 and spans approximately 37 kilobases. It consists of 15 exons that encode a protein of 724 amino acids. The gene produces multiple transcript variants through alternative splicing, generating protein isoforms with distinct functional properties.
The p85β protein contains several key structural domains:
The p85 subunits (p85α, p85β, p85γ) serve as adapter proteins that recruit p110 catalytic subunits to activated receptors at the plasma membrane. Unlike p85α (PIK3R1), which is widely expressed with multiple isoforms, p85β has more restricted tissue distribution but shows particularly high expression in brain.
PI3K/Akt signaling is initiated by activation of receptor tyrosine kinases (RTKs) at the neuronal surface. Neurotrophins such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) bind to their respective receptors (TrkB, TrkA), causing receptor autophosphorylation and recruitment of adapter proteins including Shc and IRS proteins[3].
The p85 regulatory subunit binds to phosphorylated tyrosine residues on activated receptors or adapter proteins through its SH2 domains. This recruitment positions the p110 catalytic subunit at the plasma membrane where it phosphorylates phosphatidylinositol (4,5)-bisphosphate (PIP2) to generate phosphatidylinositol (3,4,5)-trisphosphate (PIP3). The tumor suppressor PTEN (Phosphatase and Tensin Homolog) reverses this reaction, making PI3K activation a tightly regulated process.
Akt (Protein Kinase B) is the primary downstream effector of PI3K. Akt is recruited to the plasma membrane by PIP3, where it is phosphorylated at Thr308 by PDK1 and at Ser473 by mTORC2. Fully activated Akt then phosphorylates numerous substrates throughout the cell:
Cell survival: Akt phosphorylates and inhibits pro-apoptotic proteins including BAD, FoxO transcription factors, and caspase-9. This inhibition prevents mitochondrial-dependent apoptosis and promotes neuronal survival[4].
Protein synthesis: Akt activates mTORC1, which phosphorylates 4E-BP1 and p70S6K, relieving translational repression and promoting protein synthesis required for synaptic plasticity and dendritic spine formation.
Metabolism: Akt regulates glucose uptake through GLUT4 translocation and influences mitochondrial function and biogenesis through multiple mechanisms.
Gene transcription: Akt modulates the activity of transcription factors including NF-κB, CREB, and FoxO, affecting expression of survival genes and inflammatory mediators.
In Alzheimer's disease, amyloid-beta (Aβ) peptides accumulate as extracellular plaques and oligomers. Aβ oligomers are particularly toxic to synapses and neurons. Research has shown that Aβ disrupts PI3K/Akt signaling through multiple mechanisms[5][6]:
Receptor interference: Aβ binds to various neuronal receptors including NMDA receptors, AMPA receptors, and insulin receptors, interfering with their ability to activate PI3K/Akt signaling.
PTEN upregulation: Aβ exposure increases expression of the PI3K/Akt pathway inhibitor PTEN, reducing PIP3 levels and Akt activation.
Oxidative stress: Aβ-induced oxidative stress damages signaling components upstream of PI3K, including receptor tyrosine kinases and adapter proteins.
p85β alterations: Studies have identified changes in p85β expression and phosphorylation in AD brain, suggesting that regulatory subunit dysfunction contributes to pathway impairment[5:1].
Given the central role of PI3K/Akt in neuronal survival, this pathway represents a attractive therapeutic target for AD[7]:
PI3K activators: Small molecules that enhance PI3K activity could restore survival signaling in AD neurons. However, global PI3K activation may have unwanted side effects.
Akt agonists: Direct Akt activators could bypass upstream deficits. Some compounds have shown neuroprotective effects in preclinical models.
PTEN inhibitors: Blocking PTEN could increase PIP3 levels and Akt activation. However, PTEN is a tumor suppressor, and its inhibition raises cancer risk concerns.
p85β modulation: Targeting p85β specifically may provide neuroprotection with fewer systemic effects. Research suggests that p85β reduction can protect neurons from Aβ toxicity through unknown compensatory mechanisms[8].
In Parkinson's disease, the accumulation of alpha-synuclein (alpha-synuclein) in Lewy bodies and neuronal processes is a hallmark. Alpha-synuclein pathology is associated with PI3K/Akt pathway dysfunction:
Receptor dysfunction: Alpha-synuclein oligomers can damage dopaminergic neurons by interfering with neurotrophin receptor signaling, including TrkB and EGFR.
mitochondrial dysfunction: Alpha-synuclein interacts with mitochondrial proteins and can impair mitochondrial function. PI3K/Akt signaling is critical for mitochondrial maintenance and mitophagy.
ER stress: Alpha-synuclein causes endoplasmic reticulum stress, which can interfere with protein folding and signaling pathways including PI3K/Akt.
BDNF signaling through TrkB receptors is crucial for dopaminergic neuron survival. In PD, BDNF/TrkB signaling is impaired, contributing to vulnerability of dopaminergic neurons in the substantia nigra. Restoring PI3K/Akt signaling through enhanced neurotrophin signaling or downstream pathway activation represents a therapeutic strategy.
While all p85 subunits can support PI3K/Akt signaling, p85β has distinct functions in neurons. Studies using p85β-deficient neurons have revealed[4:1]:
p85β participates in synaptic plasticity mechanisms:
p85β differs from p85α in several key aspects:
PIK3R2 shows region-specific expression in the brain:
In addition to neurons, p85β is expressed in:
Several PIK3R2 variants have been associated with neurological conditions:
PIK3R2 expression and phosphorylation status in cerebrospinal fluid or blood may serve as biomarkers for:
Several strategies target PI3K/Akt for neurodegeneration:
Viral vector-mediated delivery of:
Stem cell therapies may incorporate:
Hers I, et al. PI3K signaling and neuronal function: From development to neurodegeneration. Trends Neurosci. 2020. ↩︎
Hopkins BD, et al. PI3K pathway: a key determinant of neurodegeneration. Nat Rev Neurol. 2016. ↩︎
Kim J, et al. The role of PI3K p85 subunits in neurotrophin-mediated neuronal survival. Neuroscience. 2022. ↩︎
Liu X, et al. PIK3R2/p85β regulates neuronal survival via PI3K/Akt signaling. Neurobiol Aging. 2024. ↩︎ ↩︎
Tan J, et al. PI3K regulatory subunit p85β in Alzheimer's disease pathogenesis. J Affect Disord. 2023. ↩︎ ↩︎
Wang L, et al. Dysregulated PI3K/Akt signaling in Alzheimer's disease brain. Neurobiol Aging. 2021. ↩︎
Yang J, et al. Targeting PI3K/Akt signaling for Alzheimer's disease therapy. Ageing Res Rev. 2022. ↩︎
Stabler S, et al. p85β deficiency protects neurons from Aβ toxicity. J Neurosci. 2019. ↩︎